(±)-Ibipinabant ((±)-SLV319) has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.

Ibipinabant (SLV319) is a potent, selective, and orally active antagonist of the cannabinoid CB1 receptor, demonstrating a K i of 7.8 nM and exhibiting over 1000-fold selectivity for CB1 compared to CB2 (K i =7943 nM). It is utilized in obesity and diabetes research [1] [2] [3].

(R)-SLV 319 is a potent and selective antagonist of cannabinoid receptor 1 (CB1), with a K i value of 894 nM. (R)-SLV 319 is a dextrorotatory counterpart of SLV 319 [1]